Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Q32 Bio ( (QTTB) ) is now available.
During the Annual Meeting held on April 16, 2025, Q32 Bio‘s stockholders voted on six proposals. The stockholders elected three Class I directors for a three-year term, approved an amendment to limit the liability of certain officers, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the compensation of named executive officers. Additionally, they voted for an annual advisory say-on-pay vote and approved an adjournment of the meeting if there were insufficient votes for the amendment.
The most recent analyst rating on (QTTB) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Q32 Bio stock, see the QTTB Stock Forecast page.
Spark’s Take on QTTB Stock
According to Spark, TipRanks’ AI Analyst, QTTB is a Neutral.
Q32 Bio’s overall stock score is low due to significant financial instability, negative revenue, and ongoing losses. The technical analysis shows mixed signals, while the valuation is unattractive with a negative P/E ratio and no dividends. These factors highlight the company’s current financial and operational challenges, suggesting a need for strategic changes to improve its financial health.
To see Spark’s full report on QTTB stock, click here.
More about Q32 Bio
Average Trading Volume: 154,949
Technical Sentiment Signal: Sell
Current Market Cap: $20.49M
See more data about QTTB stock on TipRanks’ Stock Analysis page.